Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274561 | 0.93 | PTGDR (0.46) | CCR2PTGDRPTGDR2CCR1 | |
| SCHEMBL15103864 | 0.92 | SMN1; SMN2 (0.52) | CCR2PTGDRPTGDR2SMN1; SMN2KMT2A | |
| SCHEMBL15103716 | 0.92 | CCR2 (0.43) | CCR2PTGDRPTGDR2SMN1; SMN2CCR1 | |
| SCHEMBL3281374 | 0.91 | PTGDR (0.41) | CCR2PTGDRPTGDR2SMN1; SMN2CCR1 | |
| SCHEMBL15103930 | 0.89 | CCR2 (0.47) | CCR2PTGDRPTGDR2SMN1; SMN2KDM4E | |
| SCHEMBL15104236 | 0.88 | PTGDR (0.45) | CCR2PTGDRPTGDR2CCR1 | |
| SCHEMBL3274249 | 0.88 | CACNA1H (0.49) | SMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL15103973 | 0.88 | CCR2 (0.49) | CCR2SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL15103962 | 0.87 | USP5 (0.45) | CCR2PTGDRPTGDR2KDM4EHSD17B10 | |
| SCHEMBL15103912 | 0.86 | CCR2 (0.48) | CCR2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | CCR2 380/4885PTGDR 117/4885PTGDR2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.